Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Triple negative
•
Breast Cancer, Non-metastatic
What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?
Related Questions
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to OFS in premenopausal women with early breast cancer?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
